“Many people with Parkinson’s are not familiar with the term ‘disease-modifying therapy’ and have not heard of it previously,” says Kate Trenam, Head of Patient Engagement (Neurosciences) at biopharmaceutical company UCB. This was the outcome of a workshop it arranged in early 2023 between people with Parkinson’s from the UK, the Netherlands and Canada alongside … Continue reading New Parkinson’s project aims to fill knowledge gap about disease-modifying therapies